[Meproscillarin in patients with renal failure and concomitant heart failure (author's transl)].
Meproscillarin is a glycoside with a high bioavailability (about 70%) and an elimination independent of the renal function. It was to be investigated whether a good cardiac effectiveness can be demonstrated during oral long-term application of meproscillarin to patients with renal failure. 29 patients with renal failure of varying degree and concomitant heart failure were daily given an oral dose of 0.75 mg of meproscillarin over 14 days. The effectiveness of the glycoside was measured as change of the electromechanical systole (QS2c) and the quotient of the diameter of heart and thorax (C/T) from the 1st--15th day. The plasma levels of the glycoside were determined on the 1st, 8th, and 15th day. There was a significant shortening of QS2c (by mean = 27 ms, P less than 0.005) and a marked decrease in the size of the heart (P less than 0.0025); heart rate and PQ-interval were only insignificantly influenced. Plasma levels of 0.95 ng/ml were found after 8 days of treatment compared to 1.25 ng/ml after 15 days. As the pharmacokinetics of the glycoside is practically not influenced by the renal function, meproscillarin represents an alternative in the treatment of patients with heart failure and impaired renal function.
D000328:Adult; D000368:Aged; D002018:Bufanolides / Q000627:therapeutic use*; D002306:Cardiac Volume / Q000187:drug effects; D004341:Drug Evaluation; D005260:Female; D006333:Heart Failure / Q000188:drug therapy*; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D007676:Kidney Failure, Chronic / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D011442:Proscillaridin / Q000031:analogs & derivatives / Q000097:blood / Q000627:therapeutic use*
D002018:Bufanolides; D011442:Proscillaridin; C009079:meproscillarin
Meproscillarin bei gleichzeitiger Nieren- und Herzinsuffizienz. Wirkungund Plasmakonzentration bei Dauernwendung.